1
|
Rea BJ, Wattiez AS, Waite JS, Castonguay WC, Schmidt CM, Fairbanks AM, Robertson BR, Brown CJ, Mason BN, Moldovan-Loomis MC, Garcia-Martinez LF, Poolman P, Ledolter J, Kardon RH, Sowers LP, Russo AF. Peripherally administered calcitonin gene-related peptide induces spontaneous pain in mice: implications for migraine. Pain 2018; 159:2306-2317. [PMID: 29994995 PMCID: PMC6193822 DOI: 10.1097/j.pain.0000000000001337] [Citation(s) in RCA: 53] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Migraine is the third most common disease in the world (behind dental caries and tension-type headache) with an estimated global prevalence of 15%, yet its etiology remains poorly understood. Recent clinical trials have heralded the potential of therapeutic antibodies that block the actions of the neuropeptide calcitonin gene-related peptide (CGRP) or its receptor to prevent migraine. Calcitonin gene-related peptide is believed to contribute to trigeminal nerve hypersensitivity and photosensitivity in migraine, but a direct role in pain associated with migraine has not been established. In this study, we report that peripherally administered CGRP can act in a light-independent manner to produce spontaneous pain in mice that is manifested as a facial grimace. As an objective validation of the orbital tightening action unit of the grimace response, we developed a squint assay using a video-based measurement of the eyelid fissure, which confirmed a significant squint response after CGRP injection, both in complete darkness and very bright light. These indicators of discomfort were completely blocked by preadministration of a monoclonal anti-CGRP-blocking antibody. However, the nonsteroidal anti-inflammatory drug meloxicam failed to block the effect of CGRP. Interestingly, an apparent sex-specific response to treatment was observed with the antimigraine drug sumatriptan partially blocking the CGRP response in male, but not female mice. These results demonstrate that CGRP can induce spontaneous pain, even in the absence of light, and that the squint response provides an objective biomarker for CGRP-induced pain that is translatable to humans.
Collapse
Affiliation(s)
- Brandon J Rea
- Department of Molecular Physiology and Biophysics, University of Iowa Carver College of Medicine, University of Iowa, Iowa City, IA, United States
| | - Anne-Sophie Wattiez
- Department of Molecular Physiology and Biophysics, University of Iowa Carver College of Medicine, University of Iowa, Iowa City, IA, United States
- Center for the Prevention and Treatment of Visual Loss, Iowa VA Medical Center, Iowa City, IA, United States
| | - Jayme S Waite
- Department of Molecular Physiology and Biophysics, University of Iowa Carver College of Medicine, University of Iowa, Iowa City, IA, United States
| | - William C Castonguay
- Department of Molecular Physiology and Biophysics, University of Iowa Carver College of Medicine, University of Iowa, Iowa City, IA, United States
| | - Chantel M Schmidt
- Department of Molecular Physiology and Biophysics, University of Iowa Carver College of Medicine, University of Iowa, Iowa City, IA, United States
| | - Aaron M Fairbanks
- Department of Molecular Physiology and Biophysics, University of Iowa Carver College of Medicine, University of Iowa, Iowa City, IA, United States
| | - Bennett R Robertson
- Department of Molecular Physiology and Biophysics, University of Iowa Carver College of Medicine, University of Iowa, Iowa City, IA, United States
| | - Cameron J Brown
- Department of Molecular Physiology and Biophysics, University of Iowa Carver College of Medicine, University of Iowa, Iowa City, IA, United States
| | - Bianca N Mason
- Department of Molecular and Cellular Biology Program, University of Iowa Carver College of Medicine, University of Iowa, Iowa City, IA, United States
| | | | | | - Pieter Poolman
- Center for the Prevention and Treatment of Visual Loss, Iowa VA Medical Center, Iowa City, IA, United States
- Department of Ophthalmology and Visual Sciences, University of Iowa Carver College of Medicine, University of Iowa, Iowa City, IA, United States
| | - Johannes Ledolter
- Center for the Prevention and Treatment of Visual Loss, Iowa VA Medical Center, Iowa City, IA, United States
- Department of Statistics and Actuarial Sciences, Tippie College of Business, University of Iowa, Iowa City, IA, United States
| | - Randy H Kardon
- Center for the Prevention and Treatment of Visual Loss, Iowa VA Medical Center, Iowa City, IA, United States
- Department of Ophthalmology and Visual Sciences, University of Iowa Carver College of Medicine, University of Iowa, Iowa City, IA, United States
| | - Levi P Sowers
- Department of Molecular Physiology and Biophysics, University of Iowa Carver College of Medicine, University of Iowa, Iowa City, IA, United States
- Center for the Prevention and Treatment of Visual Loss, Iowa VA Medical Center, Iowa City, IA, United States
| | - Andrew F Russo
- Department of Molecular Physiology and Biophysics, University of Iowa Carver College of Medicine, University of Iowa, Iowa City, IA, United States
- Center for the Prevention and Treatment of Visual Loss, Iowa VA Medical Center, Iowa City, IA, United States
- Department of Neurology, University of Iowa Carver College of Medicine, University of Iowa, Iowa City, IA, United States
| |
Collapse
|
2
|
Cardarelli PM, Rao-Naik C, Chen S, Huang H, Pham A, Moldovan-Loomis MC, Pan C, Preston B, Passmore D, Liu J, Kuhne MR, Witte A, Blanset D, King DJ. A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunol Immunother 2010; 59:257-65. [PMID: 19657637 PMCID: PMC11030752 DOI: 10.1007/s00262-009-0746-z] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2009] [Accepted: 07/20/2009] [Indexed: 12/18/2022]
Abstract
A human anti-CD19 antibody was expressed in fucosyltransferase-deficient CHO cells to generate nonfucosylated MDX-1342. Binding of MDX-1342 to human CD19-expressing cells was similar to its fucosylated parental antibody. However, MDX-1342 exhibited increased affinity for FcγRIIIa-Phe158 and FcγRIIIa-Val158 receptors as well as enhanced effector cell function, as demonstrated by increased potency and efficacy in antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis assays. MDX-1342 showed dose-dependent improvement in survival using a murine B-cell lymphoma model in which Ramos cells were administered systemically. In addition, low nanomolar binding to cynomolgus monkey CD19 and increased affinity for cynomolgus monkey FcγRIIIa was observed. In vivo administration of MDX-1342 in cynomolgus monkeys revealed potent B-cell depletion, suggesting its potential utility as a B-lymphocyte depletive therapy for malignancies and autoimmune indications.
Collapse
Affiliation(s)
- Pina M Cardarelli
- Department of Cell Biology and Pharmacology, Medarex, 1324 Chesapeake Terrace, Sunnyvale, CA 94089, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|